Everolimus in kidney transplantation

olimus in kidney transplantation Review (3358) Total Article Views Authors: Cooper JE, Christians U, Wiseman AC Published Date July 2011 Volume 2011:3 Pages 97 - 112 DOI: http://dx.doi.org/10.2147/TRRM.S13782 James E Cooper1, Uwe Christians2, Alexander C Wiseman1 1Division of Renal Diseases and Hypertension, Transplant Center, 2iC42 Integrated Solutions in Systems Biology for Clinical Research and Development, University of Colorado Denver, Aurora, CO, USA Abstract: Everolimus is a novel target of rapamycin (mTOR)-I analog that has recently been approved in combination with cyclosporine A and steroids for use in the prevention of organ rejection in kidney transplant recipients. Compared with rapamycin, everolimus is characterized by a shorter half-life and improved bioavailability. Prior to US Food and Drug Administration approval, a number of Phase II and III clinical trials were undertaken to evaluate the effectiveness of everolimus in combination with calcineurin inhibitors for preventing acute rejection and promoting allograft survival in kidney transplant recipients. In this report, we review the pharmacokinetic properties of everolimus, the clinical efficacy studies that led to its approval for use in kidney transplantation, as well as reported data on patient safety and tolerability associated with its use.